Showing results (2061-2070 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|January 18, 2013
Monitoring the effects of bevacizumab beyond progression in a murine colorectal cancer model: a functional imaging approachL Heijmen, C J A Punt, E G W Ter Voert, et al.
Investigational New Drugs|January 19, 2013
Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancerRobert Jones, Jacqueline Vuky, Tony Elliott, et al.
Investigational New Drugs|December 28, 2012
Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumorTetsuhide Ito, Takuji Okusaka, Toshirou Nishida, et al.
Investigational New Drugs|February 5, 2013
A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumorsSunil Sharma, Joachim Beck, Monica Mita, et al.
Investigational New Drugs|February 1, 1990
Experimental antitumor activity of BMY-28175 a new fermentation derived antitumor agentJ E Schurig, W C Rose, H Kamei, et al.
Investigational New Drugs|February 9, 2013
Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancerRuud P M Dings, Joseph I Levine, Susan G Brown, et al.
Investigational New Drugs|March 5, 2013
An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancerJoanne Brady, Pippa Corrie, Ian Chau, et al.
Investigational New Drugs|April 2, 2013
Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignanciesErin Schenk, Andrea E Wahner Hendrickson, Donald Northfelt, et al.
Investigational New Drugs|April 5, 2013
Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokineticsYu Sunakawa, Junji Furuse, Takuji Okusaka, et al.
Investigational New Drugs|June 5, 2013
2-Aminothiophene-3-carboxylic acid ester derivatives as novel highly selective cytostatic agentsJ Balzarini, J Thomas, S Liekens, et al.
Pageof 372